PLASMINCHEN
LIVE

Serial Number

79407754

Owner

Haema GmbH

Attorney

Deborah L. Shapiro

Filing Date

Jun 21, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PLASMINCHEN Trademark

Serial Number: 79407754 • Registration: 7910352

PLASMINCHEN is a trademark filed by Haema GmbH on June 21, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Haema GmbH (13 trademarks)

Landsteinerstraße 1

Entity Type: 98

Haema AG (13 trademarks)

Deutscher Platz 5e

Entity Type: 98

Trademark Details

Filing Date

June 21, 2024

Registration Date

August 26, 2025

Published for Opposition

July 8, 2025

Goods & Services

Medical analysis services for diagnostic and treatment purposes provided by medical laboratories in connection with blood and plasma donation and clinical medical consultations in connection with the same; Clinical medical consultation services in relation to transfusion medicine; pharmacy advice; Providing of medical information in relation to blood donation centres; Providing of medical and pharmaceutical support via telephone, namely, providing medical information generally; Medical services featuring blood fractionation or treatment; Medical services in the nature of blood sampling and collection; blood testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Pharmacy services, namely, preparation of prescriptions in pharmacies; Medical assistance; Blood bank services; Blood bank services in the nature of blood donation centres; Blood bank services in the nature of blood extraction stations; Services in the field of immunotherapy, namely, medical care; Consulting services in the field of medical care, namely, consultancy in relation to transfusion medicine and clinic hygiene, medical transfusion consultancy in clinics, in particular consultancy by doctors administering transfusions, medical transfusion testing; Medical care, namely, immunotherapy; Providing medical information, namely, medical diagnostic information through medical results; Medical care, namely, conducting medical diagnostics within the framework of conducting medical examinations; Blood bank services, namely, collecting of blood donations, including platelet donations, SDR donation being erythrocyte donation, whole blood donation, plasma donation, and autologous donation being multiple types of cellular donations from an individual; Medical care, namely, execution of medical and clinical examination services; Dietetic advisory services; Providing medical opinions in the nature of medical advice in the field of weight loss, dermatology, hematology; Health counselling; Medical care, namely, transfusion or transplantation of blood and blood components; Medical services; Medical care, namely, the use of medical equipment, instruments and apparatus for medical care purposes; Blood bank services, namely, services of packed red blood cell banks; Blood bank services, namely, services of platelet concentrate banks; Blood bank services, namely, services of leukocyte banks; Blood bank services, namely, services of blood plasma banks and collection and preservation of blood for medical and diagnostic purposes; Blood bank services, namely, blood component banks; Medical services, namely, extraction of stem cells; Remote monitoring of medical data for medical diagnosis and treatment, namely, monitoring of blood donor databases for the aforementioned purposes

Updating and maintenance of blood donor data in computer databases; Maintenance of computer databases, namely, maintenance of blood donor databases for others

Technical provision and support for data processing systems, namely, providing technology information in the field of data processing and technical support services in the nature of troubleshooting computer software problems in connection with data processing; Providing temporary use of online, non-downloadable software for accessing patient treatment databases and donor databases; Providing technological and scientific information about scientific laboratory services and blood banks, in particular medical research laboratories; Providing of scientific information derived from analysis of medical diagnostic results; Blood analysis services for scientific research purposes; Scientific laboratory services; Chemical laboratories and medical research laboratories; Scientific research in the field of physics; Chemistry services, namely, chemical analysis, chemical laboratories; Chemical analysis; Scientific testing services, namely, blood testing for scientific research purpose; Blood testing for scientific research purposes, with said testing entailing the filtration, separation and centrifugation of blood; Laboratory trials, namely, medical and scientific research in the nature of conducting clinical trials for others; Development and further development of data processing computer software and hardware in the field of laboratory medicine and blood and plasma collection; Database development services, namely, creation of medical databases in digital form; Scientific and medical research in the medical and pharmaceutical fields; Scientific and medical research in the field of chemistry and biology; Development and establishment of testing specifications and procedures for the medical industry, namely, development of medical equipment procedures and test procedures, donation procedures, and medical instrument procedures; Data processing services, namely, technical and scientific registration and processing of patient treatment data and donor data in databases; Scientific laboratory services

Medicines, in particular medicines made from blood components, fractions and preparations, with said medicines being for the treatment of diseases and disorders of the blood; Blood components, fractions and preparations, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for injection, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for automatic transplantation, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for autologous transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood, blood fractions and blood components for medical, therapeutic, and prophylactic purposes, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood plasma; Cells for medical use, namely, blood cell preparations; Health care substances and preparations, in particular for haematology, namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; Finished medical products, namely, blood for human use and blood plasma; Preparations for medical purposes, in particular haematology preparations namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; Immunotherapeutic and immunoprophylactic preparations, namely, pharmaceuticals for treating immunological diseases and disorders; Living cells for medical purposes, namely, leukocyte preparations of white blood cells; Living cells and cell fragments for medical purposes, namely, platelet and red blood cell concentrates; Blood plasma, namely, quarantine plasma and fractionated plasma; Clinical medical reagents for processing human blood and blood components for use in blood transfusions and for extracorporeal blood processing stored in bags, bottles, syringes and similar containers for storing substances such as these for medical purposes; Pharmaceutical products and haematology preparations including those for the treatment of blood and blood components, in particular infusion and transfusion solutions in the nature of blood, blood plasma, and blood substitutes for human use and pharmaceuticals for the treatment of blood diseases and disorders; Pharmaceutical blood plasma preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood products, namely, pharmaceuticals for the treatment of blood diseases, blood disorders; Cell material for autotransplantation and autotransfusion, cells for medical use; Cell material for transplantation and transfusion, namely, cells for medical use; Cell material for medical, therapeutic and prophylactic purposes, namely, cells for medical purposes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 21, 2026 FINO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 9, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 23, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 23, 2026 OPNR
GENERIC MADRID TRANSACTION SENT TO IB
Mar 14, 2026 XXSS
GENERIC MADRID TRANSACTION CREATED
Mar 14, 2026 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 26, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 26, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 26, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 2, 2025 TROA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 18, 2025 ADCH
REFUSAL PROCESSED BY IB
Feb 15, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 27, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jan 27, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 27, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 26, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 21, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 27, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 27, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 24, 2024 REPR